Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer-GOG-3059
People with Platinum-Resistant Recurrent Ovarian Cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.
You may be eligible to participate in this study if you:
- Are a female at least 18 years of age
- Have histologically confirmed and documented recurrent ovarian, fallopian tube, or peritoneal cancer
- Have available archived tumor tissue
- Received at least 1 but not more than 4 prior therapy regimens since ovarian cancer diagnosis
- Have adequate bone marrow, hepatic, and renal function
You may NOT participate in this study if you:
- Have tumors in the breast or bone
- Have primary platinum-refractory disease
- Are being treated with concurrent anticancer therapy or other interventional treatments
- Have clinically significant cardiac disease history
- Have ever participated in a study with AVB-S6-500
- Have a serious active infection requiring IV antibiotics and/or hospitalization
- Have known immunodeficiency virus (HIV) infection, hepatitis B, or C
- Are pregnant or breastfeeding
Contact Information
Stephanie Blank, MD, Principal Investigator
One Gustave L. Levy Place, Box 1170 New York, NY 10029
Phone: (212) 604 6059
Fax: (212) 824 2347
Email: stephanie.blank@mountsinai.org